In high-risk smoldering MM, personalized neoantigen vaccines (in NCT03631043 anti-MM vaccine is peptide-based, but mRNA format is supported by strong preclinical mRNA-LNP evidence [306]) and saRNA platforms targeting mutant KRAS/NRAS provide preventive interventions with curative potential [424]. The gene discussed is NRAS; the disease is Miyoshi myopathy.